Utility measurement is one of the important indicators reflecting health outcomes in pharmacoeconomic evaluation, and it has a large impact on the results of pharmacoeconomic evaluation. This paper analyzed and discussed several considerations of utility measurement defined in guidelines for pharmacoeconomic evidence submission in typical countries (regions), from the six aspects of utility indicators, target populations for utility measurement, utility measurement tools, types of multi-attribute utility instruments, utility value sets and sources of utility data. It was suggested that quality adjusted life years should be used as the utility index in the cost-utility analysis for adjustments of Chinese (except Hong Kong, Macao and Taiwan) medical insurance drug list, and the indirect methods should be used to measure the utility weights for general populations. In addition, the priority of different data sources of utility weights should be clarified.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |